Fig. S5.

In vivo therapeutic study involving the combination of ruxolitinib and Navitoclax did not prevent tumor progression in a murine model of HDLM-2 HL. There were four groups of mice, with three mice per group. Mice of the control group received vehicle alone. Mice of the ruxolitinib group received ruxolitinib at a dose of 50 mg/kg per day by s.c. inserted osmotic pumps for 2 wk. Mice of the Navitoclax group received Navitoclax at a dose of 30 mg/kg per day orally every day for 14 d. Mice of the combination group received a combination of ruxolitinb with Navitoclax at the same doses and dosing schedules as those in the ruxolitinib and Navitoclax groups. Data are presented as mean ± SD. *P < 0.01 compared with control group; ^#P < 0.05 compared with single reagent treatment groups.